Datametrex Announces Closing of Financings
Datametrex (OTC:DTMXF) closed two financings on November 14, 2025, raising aggregate gross proceeds of $5,133,500 through a common share private placement (47,918,750 shares at $0.08; $3,833,500) and a subscription receipt financing (16,250,000 receipts at $0.08; $1,300,000).
The subscription proceeds are escrowed pending satisfaction of escrow release conditions tied to the proposed acquisition of the Yuzu Payment Solution, with an escrow release deadline of December 31, 2025. Proceeds will fund Yuzu integration, merchant opportunities, a new clinic location, and working capital. Finders fees total $130,000 cash plus 1,625,000 finders warrants for the subscription financing and cash and equity finders fees for the common placement. Insider Andrew Ryu acquired 16,250,000 shares (~16.65%).
Datametrex (OTC:DTMXF) ha chiuso due finanziamenti il 14 novembre 2025, raccogliendo proventi lordi complessivi di $5,133,500 tramite una private placement di azioni ordinarie (47,918,750 azioni a $0.08; $3,833,500) e un financing di warrant di sottoscrizione (16,250,000 warrants a $0.08; $1,300,000).
I proventi da sottoscrizione sono custoditi in escrow in attesa del soddisfacimento delle condizioni di rilascio legate all'acquisizione proposta di Yuzu Payment Solution, con una scadenza di rilascio escrow fissata al 31 dicembre 2025. I proventi serviranno a finanziare l'integrazione di Yuzu, opportunità per i commercianti, una nuova sede clinica e il capitale circolante. Le commissioni per i finder ammontano a $130,000 in contanti più 1,625,000 warrant per il finanziamento di sottoscrizione e commissioni in contanti e in azioni per il collocamento di azioni ordinarie. L'insider Andrew Ryu ha acquisito 16,250,000 azioni (~16,65%).
Datametrex (OTC:DTMXF) cerró dos financiamientos el 14 de noviembre de 2025, aumentando los ingresos brutos agregados de $5,133,500 mediante una colocación privada de acciones comunes (47,918,750 acciones a $0.08; $3,833,500) y un financiamiento de recibos de suscripción (16,250,000 recibos a $0.08; $1,300,000).
Los ingresos de suscripción están en custodia (escrow) a la espera del cumplimiento de las condiciones de liberación de la custodia vinculadas a la adquisición propuesta de Yuzu Payment Solution, con una fecha límite de liberación de escrow del 31 de diciembre de 2025. Los fondos se destinarán a la integración de Yuzu, oportunidades para comerciantes, una nueva ubicación de clínica y capital de trabajo. Las comisiones para el finder ascienden a $130,000 en efectivo más 1,625,000 warrants de finder para el financiamiento de suscripción y comisiones en efectivo y en acciones para la colocación de acciones comunes. El asesor Andrew Ryu ha adquirido 16,250,000 acciones (~16.65%).
Datametrex (OTC:DTMXF)는 2025년 11월 14일 두 건의 자금조달을 마감했고, 총 $5,133,500의 총 Gross Proceeds를 주식 비공개 배정를 통해 모금했습니다(47,918,750주를 $0.08로; $3,833,500) 및 구독 영수증 자금조달 (16,250,000 영수증을 $0.08로; $1,300,000).
구독 수익은 Yuzu Payment Solution의 제안된 인수와 관련된 에스크로 해제 조건의 충족 여부에 따라 해제 기한이 2025년 12월 31일인 에스크로에 보관됩니다. 수익은 Yuzu 통합, 상인 기회, 신규 클리닉 위치 및 운전자본에 사용할 예정입니다. 파인더 수수료는 현금 $130,000와 구독 자금조달에 대한 1,625,000개의 파인더 워런트, 그리고 일반 주식 배정에 대한 현금 및 주식 수수료로 구성됩니다. 내부자 Andrew Ryu가 16,250,000주 (~16.65%)를 인수했습니다.
Datametrex (OTC:DTMXF) a clôturé deux financements le 14 novembre 2025, levant des produits bruts totaux de $5,133,500 via une placement privé d’actions ordinaires (47,918,750 actions à $0.08; $3,833,500) et un financement par actions de souscription (16,250,000 souscriptions à $0.08; $1,300,000).
Les produits de souscription sont déposés en escrow en attendant la satisfaction des conditions de déblocage liées à l’acquisition proposée de Yuzu Payment Solution, avec une date limite de déblocage en escrow fixée au 31 décembre 2025. Les produits seront destinés à l’intégration de Yuzu, aux opportunités pour les marchands, à un nouveau site de clinique et au fonds de roulement. Des frais de finder s’élèvent à $130,000 en espèces plus 1,625,000 warrants de finder pour le financement par souscription et des frais en espèces et en actions pour le placement d’actions ordinaires. L’initié Andrew Ryu a acquis 16,250,000 actions (~16,65%).
Datametrex (OTC:DTMXF) schloss am 14. November 2025 zwei Finanzierungen ab und sammelte insgesamt Bruttoerlöse von $5,133,500 durch eine private Platzierung von Stammaktien (47,918,750 Aktien zu $0.08; $3,833,500) und eine Finanzierung durch Subscription Receipts (16,250,000 Receipts zu $0.08; $1,300,000).
Die Abonnementerlöse befinden sich treuhänderisch in Verwahrung, bis die Freigabebedingungen im Zusammenhang mit dem vorgeschlagenen Erwerb von Yuzu Payment Solution erfüllt sind; eine Escrow-Freigabefrist ist auf den 31. Dezember 2025 festgelegt. Die Erlöse werden in die Integration von Yuzu, Händlermöglichkeiten, einen neuen Klinikstandort und Working Capital fließen. Vermittlungsgebühren belaufen sich auf $130,000 bar zuzüglich 1,625,000 Finder-Warrants für die Subscription Financing sowie Bar- und Aktienfindergebühren für die ordentliche Platzierung. Insider Andrew Ryu hat 16,250,000 Aktien (~16,65%) erworben.
Datametrex (OTC:DTMXF) أغلقت تمويلين في 14 نوفمبر 2025، محققة عوائد إجمالية قدرها $5,133,500 من خلال طرح خاص للأسهم العادية (47,918,750 سهماً بسعر $0.08; $3,833,500) وتمويل وصل اشتراك (16,250,000 وصولاً بسعر $0.08; $1,300,000).
يُودع عائد الاشتراك قيد الاحتجاز (escrow) انتظاراً لاستيفاء شروط إطلاق الاحتجاز المرتبطة بالاستحواذ المقترح على Yuzu Payment Solution، مع تاريخ انتهاء الإطلاق في 31 ديسمبر 2025. ستُستخدم العوائد لدمج Yuzu، وفرص التجار، وموقع عيادة جديد، ورأس المال العامل. تبلغ عمولات الوسطاء $130,000 نقداً بالإضافة إلى 1,625,000 وارنِت للباحث عن التمويل للاشتراك وعمولات نقدية وأسهم للطرح العادي. قام المساهم المطلع Andrew Ryu بشراء 16,250,000 سهم (~16.65%).
- Total gross proceeds of $5,133,500
- Subscription proceeds earmarked for Yuzu integration
- Common placement funds clinic expansion and working capital
- Insider Andrew Ryu acquired 16.65% ownership
- Acquisition and release of $1.3M escrowed funds subject to TSXV approval by Dec 31, 2025
- Finders cash commission of $130,000 equals 10% of subscription proceeds
- Potential dilution from 3,656,875 issued finders warrants overall
- All new securities subject to four months plus one day hold period
TORONTO, ON / ACCESS Newswire / November 14, 2025 / Datametrex AI Limited (the "Company" or "Datametrex'') (TSXV:DM)(FSE:D4G)(OTC:DTMXF) is pleased to announce that it has closed both its previously announced non-brokered private placement of common shares ('Common Shares Private Placement") and subscription receipt financing ("Subscription Receipt Financing") (collectively, the "Offerings"), as disclosed in the Company's press releases dated June 9,July 8, September 15, 22, 29, and November 11, 2025.
Pursuant to the Common Share Private Placement, the Company issued an aggregate of 47,918,750 common shares at a price of
The gross proceeds from the Subscription Receipt Financing will be used to integrate the Yuzu Payment Solution in Datametrex's technology division and pursuant merchant opportunities to generate revenue.
The net proceeds from the Common Share Private Placement will be used to support the Company's ongoing business expansion and development initiatives, the establishment of a new clinic location, and for general working capital purposes.
The closing of the Subscription Receipt Financing is a condition to the closing of the previously announced (see press release dated September 15, 2025) proposed acquisition of the Yuzu Payment Solution (the "Acquisition"). The Subscription Receipts were created and issued pursuant to terms of a subscription receipt agreement dated November 14, 2025 (the "Subscription Receipt Agreement") between the Company and TSX Trust Company as subscription receipt agent (the "Subscription Receipt Agent"). The gross proceeds of the Subscription Receipt Financing have been deposited in escrow with the Subscription Receipt Agent pending satisfaction of the Escrow Release Conditions (as defined below) in accordance with the Subscription Receipt Agreement.
Each Subscription Receipt will be deemed to be automatically exchanged, without payment of additional consideration or further action by the holder thereof into one (1) common share of the Company immediately upon the satisfaction or waiver of the Escrow Release Conditions on or before December 31, 2025 (the "Escrow Release Deadline"). Pursuant to the terms of the Subscription Receipt Agreement, each Subscription Receipt shall be automatically exchanged into one Common Share of the Company upon:
the completion, satisfaction or waiver of all conditions precedent to the Acquisition;
receipt of all required approvals including regulatory and TSXV approval; and
delivery of a notice to the Subscription Receipt Agent confirming all conditions to the Acquisition having been met or waived
(collectively, the "Escrow Release Conditions")
If the Escrow Release Conditions are not satisfied at or before the Escrow Release Deadline, each of the then issued and outstanding Subscription Receipts will be cancelled and the Subscription Receipt Agent will return to each holder of Subscription Receipts an amount equal to the aggregate issue price of Subscription Receipts held by such holder. To the extent escrowed funds are insufficient to refund such amounts to each holder of the Subscription Receipts, the Company shall be liable for and will contribute such amounts as necessary to satisfy the shortfall.
In connection with the Subscription Receipt Financing, finders ("Finders) are entitled to be paid a cash commission of
In connection with the Common Share Private Placement, the Company has paid aggregate cash finder's fees of
Insiders of the Company have participated in the Common Share Private Placement by subscribing for an aggregate of 5,925,000 Common Shares. The participation by the insiders in the Common Share Private Placement is considered to be a "related party transaction" as defined for the purposes of Multinational Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The related party transaction is exempt from the formal valuation and minority approval requirements pursuant to sections 5.5 (a) (b) and (c) and 5.7(1) (a) and (b) of MI 61-101 as the Company is not listed on a specified market, the transaction was a distribution of securities for cash and neither the fair market value of the Common Shares distributed to nor the consideration received from the related parties exceeded
Prior to the completion of the Offerings, Mr. Andrew Ryu ("Ryu") held no Common Shares or other securities of the Company. Upon completion of the Offerings, Mr. Ryu held an aggregate of 16,250,000 Common Shares, representing approximately
The Offerings are subject to the receipt of final approval of the TSXV and completion of the proposed Acquisition remains subject to a number of customary conditions including receipt of final approval of the TSXV. The Acquistion is expected to close no later than the Escrow Release Deadline.
All securities issued under the Offerings are subject to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable Canadian securities laws.
The completion of these Offerings marks another key step forward in Datametrex's continued growth strategy, strengthening the Company's balance sheet and supporting its vision of expanding its operations across new markets.
About Datametrex
Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, and Healthcare. The Company specializes in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.
For more on Datametrex, please visit our Company website.
For Additional Information
Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
info@datametrex.com
(416) 318-6501
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.
Forward-Looking Statements
This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.
While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.
Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.
This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.
###
SOURCE: DataMetrex AI Ltd.
View the original press release on ACCESS Newswire